Welcome to our dedicated page for abrdn Life Sciences Investors SEC filings (Ticker: HQL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the real story inside a closed-end fund’s disclosures can feel like navigating biotech research itself. abrdn Life Sciences Investors’ filings span traditional corporate forms and fund-specific reports, mixing 10-K narratives with N-CSR portfolio tables and Form 4 insider trades linked to FDA catalysts. If you are searching for “abrdn Life Sciences Investors SEC filings explained simply”, you are in the right place.
Stock Titan’s AI breaks down each document—whether it’s an annual report 10-K simplified, a quarterly earnings report 10-Q filing, or an 8-K material events explained—and highlights what matters: shifts in biotech allocations, NAV premium or discount trends, dividend policy changes, and risk updates on clinical pipelines. Our engine also flags “abrdn Life Sciences Investors insider trading Form 4 transactions” in real time, so you can monitor executive stock transactions before they hit your portfolio model.
Every filing arrives within minutes of EDGAR publication and is paired with:
- AI-powered summaries that translate dense accounting notes into clear talking points
- Keyword search to track executive compensation in the proxy statement
- Side-by-side comparisons for quarter-over-quarter portfolio changes
- Instant alerts on “abrdn Life Sciences Investors Form 4 insider transactions real-time”
Whether you want a concise earnings report filing analysis, need to understand reserve levels for biotech follow-ons, or simply prefer “understanding abrdn Life Sciences Investors SEC documents with AI”, this page delivers the insight required to make informed decisions—without sifting through hundreds of pages.
Saba Capital Management and affiliates report a significant position in abrdn Life Sciences Investors. In this Amendment No. 10, Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein disclose beneficial ownership of 2,002,516 common shares of abrdn Life Sciences Investors, representing 6.77% of the outstanding shares, based on 29,598,692 shares outstanding as of 9/30/25.
The reporting persons have shared voting and dispositive power over 2,002,516 shares and no sole voting or dispositive power. They state that approximately $26,261,523 was paid to acquire the common shares, using investor subscription proceeds, capital appreciation, and margin borrowings in the ordinary course of business, with positions in margin accounts pledged as collateral.
All reported trades between 11/24/25 and 1/7/26 were executed in the open market, as detailed in Schedule A. Dividends and sale proceeds from these shares are payable to the funds and accounts advised by Saba Capital.
abrdn Life Sciences Investors filed an initial insider ownership report for a vice president of abrdn. The filing, dated 12/09/2025 as the event date, identifies the individual as an officer of the fund. The report states in the remarks that no securities are beneficially owned by the reporting person. This Form 3 establishes the officer’s ownership status for regulatory disclosure purposes.
abrdn Life Sciences Investors reported that one of its directors acquired 7,923 shares of its common stock on 12/16/2025 at a price of $16.8818 per share. Following this transaction, the director directly beneficially owned 7,923 shares of the company.
Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein filed Amendment No. 9 to Schedule 13D reporting beneficial ownership of 2,274,356 common shares of abrdn Life Sciences Investors (HQL), equal to 7.88% of the outstanding shares based on 28,872,416 shares outstanding as of 3/31/25. The event triggering this filing occurred on 11/21/2025.
All reporting persons share voting and dispositive power over these shares and have no sole voting or dispositive authority. Approximately $29,826,505 was paid to acquire the reported position, using investor subscription proceeds, capital appreciation, and ordinary-course margin borrowings. Funds and accounts advised by Saba Capital are entitled to dividends and sale proceeds. This amendment updates Items 3, 5 and 7, and lists Schedule A as an exhibit detailing recent open-market transactions.
Saba Capital and affiliated persons report beneficial ownership of 2,586,652 common shares of abrdn Life Sciences Investors, representing 8.96% of the outstanding class based on 28,872,416 shares. The filing amends prior Schedule 13D disclosures and states acquisition funds came from investor subscriptions, capital appreciation and margin borrowings, with approximately $33,922,037 paid for the shares. The reporting group consists of Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein. The positions reported are held with shared voting and dispositive power and the advised funds retain rights to dividends and sale proceeds. Transactions executed in the open market since the prior filing are noted and incorporated by reference.
Saba Capital Management, L.P. reported insider sales of abrdn Life Sciences Investors (HQL) common stock on a Form 4. The filing lists two dispositions: 6,989 shares sold on 09/19/2025 at $14.10 and 41,623 shares sold on 09/22/2025 at $14.14. After the reported transactions, Saba Capital’s beneficial ownership is shown as 2,837,633 shares (indirect), down from 2,879,256 shares following the earlier sale. The Form identifies the reporting entity as Saba Capital Management, L.P., with signatures dated 09/23/2025.
Saba Capital Management, L.P. reported two insider sales of abrdn Life Sciences Investors (HQL) common stock. On 09/17/2025 the filer sold 24,328 shares at $13.99, leaving 2,926,453 shares beneficially owned indirectly. On 09/18/2025 the filer sold 40,208 shares at $14.07, leaving 2,886,245 shares beneficially owned indirectly.
The Form 4 is signed by representatives of Saba Capital (Zachary Gindes and Boaz Weinstein) on 09/19/2025. The filing identifies the reporting person as a Director and reports indirect beneficial ownership of the disclosed shares.
Saba Capital Management, L.P. reported insider sales of 700 shares of abrdn Life Sciences Investors (HQL) on 09/15/2025 at $14.13 and 2,026 shares on 09/16/2025 at $13.99. After these transactions the filer beneficially owned 2,950,781 shares indirectly. The filing lists the reporting relationship as a Director and is signed by Zachary Gindes and Boaz Weinstein on 09/17/2025. No derivative transactions were reported.
Saba Capital Management, L.P. reported a Form 4 showing an insider sale of 15,116 shares of abrdn Life Sciences Investors (HQL) on 09/11/2025 at a price of $14.28 per share. After the transaction, the reporting person beneficially owned 2,953,507 shares indirectly. The filing reflects compliance with Section 16 reporting for a director-level reporting person.
abrdn Life Sciences Investors (HQL) insiders reported an indirect sale of common stock. On 09/02/2025 Saba Capital Management, L.P. and Boaz Weinstein reported a disposition of 14,083 shares at $14.04 per share. After the sale, the reporting persons beneficially owned 2,968,623 shares indirectly. The Form 4 was filed by more than one reporting person and signed on 09/04/2025.
FAQ
What is the current stock price of abrdn Life Sciences Investors (HQL)?
What is the market cap of abrdn Life Sciences Investors (HQL)?
